Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Shares Outstanding (Diluted Average): 2023-2025

Historic Shares Outstanding (Diluted Average) for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $88.0 million.

  • Immunome's Shares Outstanding (Diluted Average) rose 46.10% to $88.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.0 million, marking a year-over-year increase of 46.10%. This contributed to the annual value of $58.6 million for FY2024, which is 195.51% up from last year.
  • Immunome's Shares Outstanding (Diluted Average) amounted to $88.0 million in Q3 2025, which was up 1.09% from $87.0 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's Shares Outstanding (Diluted Average) peaked at $88.0 million during Q3 2025, and registered a low of $12.2 million during Q1 2023.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $49.2 million, with a median of $58.6 million in 2024.
  • Data for Immunome's Shares Outstanding (Diluted Average) shows a peak YoY spiked of 393.39% (in 2024) over the last 5 years.
  • Over the past 3 years, Immunome's Shares Outstanding (Diluted Average) (Quarterly) stood at $19.8 million in 2023, then soared by 195.51% to $58.6 million in 2024, then soared by 46.10% to $88.0 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $88.0 million for Q3 2025, versus $87.0 million for Q2 2025 and $79.4 million for Q1 2025.